查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844144

食品過敏診斷和治療市場（按產品類型、過敏原類型、最終用戶和分銷管道分類）—2025-2032年全球預測

Food Allergy Diagnostics & Therapeutics Market by Product Type, Allergen Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，食品過敏診斷和治療市場規模將達到 145.7 億美元，複合年成長率為 10.75%。

主要市場統計數據
基準年 2024 64.3億美元
預計年份：2025年 71.4億美元
預測年份：2032年 145.7億美元
複合年成長率 (%) 10.75%

本書簡明扼要地介紹了食物過敏診斷和治療方法領域的最新進展，重點關注患者預後、技術創新和政策促進因素。

食品過敏診斷和治療領域正經歷結構性發展，這主要得益於臨床創新、護理模式的轉變以及支付方和監管機構日益成長的關注。能夠更精準地識別致敏模式的診斷技術正與旨在實現持續免疫調節的治療方法相融合，從而創造了一個臨床醫生、實驗室技術人員和行業合作夥伴必須比以往任何時候都更加緊密合作的環境。

隨著臨床界廣泛採用成分解析診斷和居家篩檢，治療方法策略正從控制症狀轉向緩解疾病療法。這兩大趨勢迫使相關人員重新評估臨床路徑、實證策略和商業模式。未來成功的舉措將整合嚴格的臨床檢驗、包含醫保支付方參與的衛生經濟學原理以及以患者為中心的清晰價值提案，從而將實驗室技術的進步轉化為更佳的治療效果和更高效的醫療服務。

識別影響診斷和治療管道的臨床實踐、技術應用、支付方參與和患者行為方面的變革性轉變

近年來，過敏症的診療和商業化模式正經歷許多重大曲折點。多重檢測和分子成分診斷等治療技術的進步，為臨床醫生提供了詳細的過敏原資訊，有助於精準治療；同時，數位化工具和遠端檢測也拓展了篩檢和長期監測的範圍。此外，治療方法也不斷多樣化。儘管傳統的抗組織胺和急性干預措施仍然是治療的基石，但免疫療法和生技藥品正推動治療模式轉向長期疾病管理。

隨著技術和臨床實踐的變革，支付方框架和監管預期也在不斷演變，迫使相關人員證明其真正的益處和成本效益。便利性、安全性和生活品質的顯著改善正在推動患者接受新技術。總而言之，這些變化共同表明，整合策略對於技術的永續應用和患者療效的顯著改善至關重要。

評估2025年美國關稅對供應鏈、試劑採購、臨床檢測、定價策略和國際合作的影響

2025年生效的政策措施將導致關稅上調和關稅結構調整，這對從事過敏診斷和治療的製造商、經銷商和臨床實驗室將帶來重要考量。在涉及專業試劑、檢測組件和生技藥品成分跨境運輸的供應鏈中，其影響將最為顯著。隨著運輸管道日益複雜，採購團隊正在重新調整籌資策略的風險，並確保供應的連續性。

臨床試驗申辦方和研究機構都在調整試驗方案和預算，以因應進口材料和外包檢測服務可能帶來的成本上漲。這些調整通常包括儘早與生產合作夥伴接洽、考慮區域性生產方案以及重視庫存規劃。商業團隊也在根據需要重新調整定價和合約條款。同時，支付方也積極參與討論高成本產品和新技術對報銷的影響。此外，優先考慮供應鏈多元化、加強供應商合約以及加快關鍵投入品的在地化進程，有助於減輕關稅帶來的衝擊，並確保研發和交付按時完成。

深入洞察產品類型、過敏原類別、最終用戶和分銷管道等關鍵細分因素將如何推動臨床應用和商業策略的發展。

透過從產品類型、過敏原特異性、終端用戶環境和分銷管道等角度審視市場，細分分析能夠揭示可操作的洞察。診斷測試包括家庭過敏測試、成分特異性診斷、皮膚點刺試驗和特異性IgE測試，每種測試都有不同的臨床效用和普及程度，會影響實驗室工作流程和照護現場決策。雖然抗組織胺和急性期護理仍然是治療的關鍵，但經經皮、口服和皮下途徑給藥的免疫療法與單株抗體一起構成了長期治療模式，每種療法都需要量身定做的實證策略。

雞蛋、牛奶、花生、堅果、貝類、芝麻、大豆、魚類和小麥過敏在診斷、病患教育需求和治療耐受性方面各有不同。包括醫院實驗室、照護現場(POC) 機構、參考文獻實驗室和研究機構在內的終端用戶，在伴隨診斷的採購行為、技術能力和偏好也存在差異。此外，包括診所和診斷中心、醫院、線上平台和病人歷程的分銷管道，決定了患者的就診途徑和商業模式。整合這些細分資訊有助於制定與臨床工作流程和病患就診路徑相契合的產品定位、證據產生和市場策略的策略決策。

透過對美洲、歐洲、中東和非洲以及亞太地區監管、報銷和市場動態的洞察

區域動態對診斷和治療創新技術的研發、應用和報銷方式有顯著影響。美洲地區臨床研究持續活躍，並展現出多元化的商業模式，強調在門診和住院環境中快速整合新的診斷方法和專科治療。相較之下，歐洲、中東和非洲的監管和報銷體係錯綜複雜，各國之間存在著協調努力和差異，因此需要有針對性的證據整合和區域性定價策略。

亞太地區是一個多元化的區域，擁有高產能的製造地和快速發展的患者准入計劃，該地區的各項工作通常圍繞監管協調、技術轉移和可擴展的分銷解決方案展開。在亞太地區，跨境研究合作、監管協調以及對本地臨床能力的投資是普遍存在的趨勢，這些都有助於擴大應用範圍並增強供應鏈的韌性。了解這些區域差異對於調整商業化策略以及優先投資於監管和支付方合作至關重要。

深入剖析診斷和治療領域主要企業領導企業的競爭格局、策略夥伴關係、研發投資和優先事項。

主要企業之間的競爭動態呈現出差異化的產品組合、策略夥伴關係以及針對性研發投入的特徵。一些公司專注於多重診斷平台和分子水平檢測，以實現更精準的患者分層；而另一些公司則優先開發旨在改變疾病進程的免疫療法和生技藥品。隨著整合醫療模式需要統一的證據和協作式的研發路徑，診斷創新者和治療藥物開發商之間的合作也日益普遍。

投資策略體現了近期商業性優先事項與長期產品線開發之間的平衡。策略夥伴關係，包括經銷協議、研發合作和授權協議，能夠加速取得互補能力。營運重點通常在於增強生產韌性、確保試劑供應以及實施可擴展的品質系統以滿足多樣化的監管要求。在臨床和物流可靠性至關重要的市場中，能夠清晰傳達臨床價值、使證據產生與支付方需求相符並建立可互通的臨床工作流程的相關人員將獲得競爭優勢。

建議領導者加快患者就醫速度、最佳化供應鏈、與支付方合作，並優先考慮過敏治療領域具有影響力的創新。

該領域的領導者應採取一系列務實且以患者為中心的措施，將創新轉化為可近的醫療服務。首先，在研發早期階段就應使證據產生與支付方和監管機構的期望保持一致，確保臨床檢驗、衛生經濟學和真實世界證據的收集能夠支持報銷和製劑配方方面的討論。其次，透過關鍵試劑供應商多元化、評估區域生產方案以及建立緊急庫存來最佳化供應鏈策略，從而降低貿易政策波動帶來的風險。

第三，優先考慮互通性和臨床醫生參與，設計能夠無縫融入現有臨床工作流程並提供清晰決策支援的診斷和治療方法方案。第四，投資於病患教育和支援服務，以提高病患對免疫療法的依從性，並確保居家檢測的安全合理使用。最後，尋求選擇性的夥伴關係，以加速市場准入並擴大地域覆蓋範圍，同時保持核心技術優勢。結合這些步驟，企業能夠有效管理風險、加速產品推廣，並向臨床醫生、支付者和患者展現可衡量的價值。

一套透明的調查方法，詳細闡述了資料來源、調查方法和資料來源、檢驗步驟以及倫理考量，能夠提供可靠的產業洞察。

本調查方法基於結構化流程，結合了主要相關利益者參與、嚴謹的二次綜合分析和迭代檢驗。主要資訊來源包括與臨床醫生、實驗室主任、公司高管、支付方和患者權益倡導代表的訪談和諮詢，以確保研究結果反映現實世界的決策因素。二次綜合分析則利用同行評審文獻、監管指南、臨床試驗註冊庫和公開的技術資訊，為主要見解提供背景資訊。

分析方法包括定性主題分析、跨細分維度的比較評估以及基於情境的供應鍊和政策影響評估。檢驗步驟包括與專家最後覆核關鍵結論，並透過三角測量法協調不同觀點。出於倫理考量，訪談資料已匿名化處理，且研究限制已明確說明。這些方法的結合確保了分析結果的穩健性、可操作性，並與臨床、商業和政策領域密切相關。

區域結論：摘要對相關人員的影響，並重點介紹能夠推進創新路徑、提升營運韌性和改善病患預後的合作模式。

所審查的證據表明，過敏診斷和治療的持續進步依賴於技術開發、證據生成、供應鏈韌性和相關人員參與等多方面的協調努力。診斷準確性有助於更好地對患者進行分層，而多樣化的治療方法則為從症狀控制轉向疾病改善提供了契機。同時，監管和報銷方面的實際情況要求有針對性的證據和與支付方的積極溝通，才能實現常規臨床應用。

展望未來，擁有整合跨職能規劃（包括臨床檢驗、切實可行的部署管道和以患者為中心的支援）的組織，將更有能力將創新轉化為可衡量的成果。產業、臨床系統和政策相關人員之間的合作對於克服與醫療服務可近性、醫療負擔能力和營運複雜性相關的障礙仍然至關重要。在此背景下，清晰的策略重點和嚴謹的執行將決定舉措能帶來最大的臨床和商業性價值。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大多重免疫檢測平台規模，用於同時檢測多種食物過敏原特異性IgE生物標記物
  • 生技創新企業與領先製藥公司擴大策略聯盟，推動花生過敏脫敏口服免疫療法
  • 將數位健康應用程式與穿戴式感測器技術結合，即時監測食物過敏情況。
  • 增加對重組低過敏性蛋白疫苗和針對主要食物過敏原的胜肽免疫療法的投資
  • 採用次世代定序技術對兒科病患的個別過敏致敏模式進行全面分析

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 按產品類型分類的食物過敏診斷和治療市場

  • 診斷測試
    • 家用過敏測試
    • 組件解決方案診斷
    • 皮膚點刺試驗
    • 特異性IgE檢測
  • 治療產品
    • 抗組織胺藥
    • 緊急治療
    • 免疫療法
      • 表皮免疫療法
      • 口服免疫療法
      • 皮下免疫療法
    • 單株抗體

9. 按過敏原類型分類的食物過敏診斷與治療市場

  • 雞蛋過敏
  • 魚類過敏
  • 牛奶過敏
  • 花生過敏
  • 芝麻過敏
  • 貝類過敏
  • 大豆過敏
  • 樹堅果過敏
  • 小麥過敏

第10章：按最終用戶分類的食物過敏診斷和治療市場

  • 醫院檢查室
  • 照護現場環境
  • 參考實驗室
  • 研究所

11. 按分銷管道分類的食物過敏診斷和治療市場

  • 診所和診斷中心
  • 醫院
  • 線上
  • 藥局

12. 各地區食物過敏診斷及治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：按群體分類的食物過敏診斷和治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國食物過敏診斷及治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Quest Diagnostics Incorporated
    • Eurofins Scientific SE
    • bioMerieux SA
    • Abbott Laboratories
    • Nestle Health Science SA
    • ALK-Abello A/S
    • DBV Technologies SA
    • Stallergenes Greer International SA
    • Aimmune Therapeutics LLC
Product Code: MRR-ED54C46E8118

The Food Allergy Diagnostics & Therapeutics Market is projected to grow by USD 14.57 billion at a CAGR of 10.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.43 billion
Estimated Year [2025] USD 7.14 billion
Forecast Year [2032] USD 14.57 billion
CAGR (%) 10.75%

A concise introduction to the evolving food allergy diagnostics and therapeutics landscape emphasizing patient outcomes, innovation, and policy drivers

The food allergy diagnostics and therapeutics sector is experiencing a period of structured advancement driven by clinical innovation, changing care models, and intensified attention from payers and regulators. Diagnostic technologies that enable more precise identification of sensitization patterns are converging with therapeutic approaches that seek durable immune modulation, producing an environment in which clinicians, laboratorians, and industry partners must coordinate more closely than ever before.

As the clinical community adopts component-resolved diagnostics and at-home screening options, therapeutic pipelines are simultaneously shifting from symptom control toward disease-modifying approaches. This dual movement compels stakeholders to reassess clinical pathways, evidence generation strategies, and commercial models. Moving forward, successful initiatives will integrate rigorous clinical validation, payer-engaged health economic rationale, and clear patient-centered value propositions to translate laboratory advances into improved outcomes and more efficient care delivery.

Identifying transformative shifts in clinical practice, technology adoption, payer engagement, and patient behavior reshaping diagnostic and therapeutic routes

Recent years have seen multiple inflection points that collectively redefine how allergy care is delivered and commercialized. Technological advances such as multiplexed assays and molecular component diagnostics are providing clinicians with granular profiles that inform precision treatment, while digital tools and remote testing expand the reach of screening and longitudinal monitoring. Concurrently, therapeutic approaches have diversified: traditional antihistamines and emergency interventions remain foundational, but immunotherapy modalities and biologic agents are prompting shifts toward long-term disease management.

Alongside technology and clinical practice changes, payer frameworks and regulatory expectations are evolving, pressing stakeholders to demonstrate real-world benefits and cost-effectiveness. Patient expectations are also a powerful driver; convenience, safety, and measurable improvements in quality of life are guiding uptake. Taken together, these shifts create a landscape in which integrated strategies across diagnostics, therapeutics, and care delivery models are essential for sustainable adoption and meaningful improvements in patient outcomes.

Assessing impact of US tariffs from 2025 on supply chains, reagent sourcing, clinical trials, pricing strategies and international collaboration

Policy actions implemented in 2025 that increase or alter tariff structures have introduced material considerations for manufacturers, distributors, and clinical laboratories engaged in allergy diagnostics and therapeutics. The effects are most visible along supply chains where specialized reagents, assay components and biologic drug ingredients cross borders. As shipping paths become more complex, procurement teams are reallocating sourcing strategies to reduce exposure to tariff volatility and to preserve continuity of supply.

Clinical trial sponsors and research institutions are likewise adapting protocols and budgets to accommodate potential cost escalations associated with imported materials or outsourced testing services. These adjustments frequently involve earlier engagement with manufacturing partners, consideration of regional manufacturing alternatives, and a heightened focus on inventory planning. Commercial teams are reallocating pricing and contracting levers when necessary, while payers are being engaged proactively to discuss the implications for reimbursement of higher-cost products or new technologies. In the near term, organizations that prioritize supply chain diversification, strengthen supplier agreements, and accelerate localization of key inputs will be better positioned to mitigate tariff-induced disruptions and sustain development and delivery timelines.

Key segmentation insights on how product types, allergen categories, end users and distribution channels drive clinical uptake and commercial strategy

Segmentation analysis reveals practical insights when examined through the lens of product type, allergen specificity, end-user setting, and distribution pathway. Diagnostic tests encompass at-home allergy tests, component resolved diagnostics, skin prick tests, and specific IgE tests, each presenting distinct clinical utility and adoption profiles that influence laboratory workflows and point-of-care decision making. Therapeutic products include antihistamines and emergency treatments that remain essential, while immunotherapy-delivered via epicutaneous, oral, or subcutaneous routes-together with monoclonal antibodies shape the longer-term management paradigm and demand tailored evidence strategies.

Allergen type introduces further nuance: egg, milk, peanut, tree nut, shellfish, sesame, soy, fish, and wheat allergies present different diagnostic challenges, patient education needs, and therapy tolerability considerations. End users such as hospital laboratories, point-of-care settings, reference laboratories, and research institutes exhibit varying procurement behaviors, technical capabilities and preferences for companion diagnostics. Finally, distribution channels including clinics and diagnostic centers, hospitals, online platforms and pharmacies determine patient access pathways and commercial models. Integrating these segmentation dimensions supports strategic decisions about product positioning, evidence generation, and go-to-market approaches that align with clinical workflows and patient journeys.

Regional insights on how the Americas, Europe, Middle East & Africa and Asia-Pacific present distinct regulatory, reimbursement and market dynamics globally

Regional dynamics materially influence how diagnostic and therapeutic innovations are developed, adopted, and reimbursed. The Americas continue to demonstrate robust clinical research activity and a diverse set of commercial models that emphasize rapid integration of new diagnostics and specialty therapeutics in both ambulatory and hospital settings. In contrast, Europe, Middle East & Africa offer a complex regulatory and reimbursement mosaic where harmonization efforts coexist with country-level variability, requiring targeted evidence packages and localized pricing strategies.

Asia-Pacific presents a heterogeneous mix of high-capacity manufacturing hubs and rapidly expanding patient access initiatives; engagement in this region often centers on regulatory alignment, technology transfer, and scalable distribution solutions. Across all regions, cross-border collaboration in research, harmonized regulatory interactions, and investment in local clinical capacity are recurring themes that enable broader adoption and more resilient supply chains. Understanding these regional differences is essential for calibrating commercialization efforts and prioritizing investment in regulatory and payer engagement.

Key companies insights on competitive positioning, strategic partnerships, R&D investment and priorities among diagnostic and therapeutic leaders

Competitive dynamics among leading companies in diagnostics and therapeutics are characterized by differentiated portfolios, strategic partnerships, and targeted investment in research and development. Some firms are concentrating on multiplexed diagnostic platforms and molecular-level assays to enable more precise patient stratification, while others prioritize development of immunotherapies and biologics designed to alter disease trajectory. Collaboration between diagnostic innovators and therapeutic developers is increasingly common as integrated care models require aligned evidence and co-development pathways.

Investment strategies reflect a balance between near-term commercial priorities and long-term pipeline development. Strategic partnerships-including distribution agreements, R&D collaborations and licensing arrangements-are accelerating access to complementary capabilities. Operational priorities often focus on strengthening manufacturing resilience, securing reagent supply, and implementing scalable quality systems to meet diverse regulatory requirements. Stakeholders that clearly communicate clinical value, align evidence generation with payer needs, and establish interoperable clinical workflows gain advantage in a market where clinical credibility and logistical reliability matter most.

Recommendations for leaders to accelerate patient access, optimize supply chains, align with payers, and prioritize impactful innovation for allergy care

Leaders in the field should adopt a pragmatic and patient-centered set of actions to translate innovation into accessible care. First, align evidence generation with payer and regulatory expectations early in development so that clinical validation, health economics and real-world evidence collection support reimbursement and formulary discussions. Second, optimize supply chain strategies by diversifying suppliers for critical reagents, evaluating regional manufacturing options, and establishing contingency inventory to reduce exposure to trade-policy fluctuations.

Third, prioritize interoperability and clinician engagement by designing diagnostics and therapy introduction programs that fit seamlessly into existing clinical workflows and deliver clear decision support. Fourth, invest in patient education and support services to improve adherence with immunotherapy regimens and to ensure safe, appropriate use of at-home testing. Finally, pursue selective partnerships that accelerate market entry and expand geographic footprint without diluting core technical competencies. Taken together, these steps help organizations manage risk, accelerate uptake, and demonstrate measurable value to clinicians, payers and patients.

Transparent research methodology outlining data sources, analytical approaches, validation steps, and ethical considerations to produce robust industry insights

This research is grounded in a structured methodology that combines primary stakeholder engagement, rigorous secondary-source synthesis, and iterative validation. Primary inputs include interviews and consultations with clinicians, laboratory directors, commercial executives, payers, and patient advocacy representatives to ensure findings reflect real-world decision drivers. Secondary synthesis draws on peer-reviewed literature, regulatory guidance, clinical trial registries and publicly available technical information to contextualize primary insights.

Analytical approaches incorporate qualitative thematic analysis, comparative assessment across segmentation dimensions, and scenario-based evaluation of supply chain and policy impacts. Validation steps include cross-checking key conclusions with subject-matter experts and reconciling divergent perspectives through triangulation. Ethical considerations guide anonymization of interview data and the transparent representation of limitations. This combination of methods ensures the analysis is robust, actionable, and relevant to clinical, commercial and policy audiences.

Regional conclusion summarizing implications for stakeholders, emphasizing innovation pathways, operational resilience, collaborative models advancing patient outcomes

The body of evidence examined indicates that sustained progress in allergy diagnostics and therapeutics depends on coordinated efforts across technological development, evidence generation, supply chain resilience and stakeholder engagement. Diagnostic precision enables better patient stratification, while diversified therapeutic modalities offer opportunities to shift from symptom control to disease modification. At the same time, regulatory and reimbursement realities require targeted evidence and constructive payer engagement to achieve routine clinical adoption.

Looking ahead, organizations that integrate cross-functional planning-combining clinical validation, pragmatic deployment pathways, and patient-centered support-will be best placed to convert innovation into measurable outcomes. Collaboration across industry, clinical systems and policy stakeholders will remain essential for overcoming barriers related to access, affordability and operational complexity. In this context, clear strategic priorities and disciplined execution will determine which initiatives deliver the greatest clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of multiplexed immunoassay platforms for simultaneous detection of multiple food allergen specific IgE biomarkers
  • 5.2. Growing strategic collaborations between biotech innovators and big pharma to advance oral immunotherapy for peanut allergy desensitization
  • 5.3. Integration of digital health applications and wearable sensor technologies for real-time monitoring of allergic reactions to food intake
  • 5.4. Rising investment in recombinant hypoallergenic protein vaccines and peptide-based immunotherapies targeting major food allergens
  • 5.5. Adoption of next-generation sequencing technologies for comprehensive profiling of individual allergic sensitization patterns in pediatric patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Food Allergy Diagnostics & Therapeutics Market, by Product Type

  • 8.1. Diagnostic Tests
    • 8.1.1. At-Home Allergy Tests
    • 8.1.2. Component Resolved Diagnostics
    • 8.1.3. Skin Prick Tests
    • 8.1.4. Specific IgE Tests
  • 8.2. Therapeutic Products
    • 8.2.1. Antihistamines
    • 8.2.2. Emergency Treatments
    • 8.2.3. Immunotherapy
      • 8.2.3.1. Epicutaneous Immunotherapy
      • 8.2.3.2. Oral Immunotherapy
      • 8.2.3.3. Subcutaneous Immunotherapy
    • 8.2.4. Monoclonal Antibodies

9. Food Allergy Diagnostics & Therapeutics Market, by Allergen Type

  • 9.1. Egg Allergy
  • 9.2. Fish Allergy
  • 9.3. Milk Allergy
  • 9.4. Peanut Allergy
  • 9.5. Sesame Allergy
  • 9.6. Shellfish Allergy
  • 9.7. Soy Allergy
  • 9.8. Tree Nut Allergy
  • 9.9. Wheat Allergy

10. Food Allergy Diagnostics & Therapeutics Market, by End User

  • 10.1. Hospital Laboratories
  • 10.2. Point-Of-Care Settings
  • 10.3. Reference Laboratories
  • 10.4. Research Institutes

11. Food Allergy Diagnostics & Therapeutics Market, by Distribution Channel

  • 11.1. Clinics & Diagnostic Centers
  • 11.2. Hospitals
  • 11.3. Online
  • 11.4. Pharmacies

12. Food Allergy Diagnostics & Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Food Allergy Diagnostics & Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Food Allergy Diagnostics & Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Quest Diagnostics Incorporated
    • 15.3.3. Eurofins Scientific SE
    • 15.3.4. bioMerieux SA
    • 15.3.5. Abbott Laboratories
    • 15.3.6. Nestle Health Science S.A.
    • 15.3.7. ALK-Abello A/S
    • 15.3.8. DBV Technologies S.A.
    • 15.3.9. Stallergenes Greer International S.A.
    • 15.3.10. Aimmune Therapeutics LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY AT-HOME ALLERGY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN PRICK TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIFIC IGE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EMERGENCY TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EPICUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ORAL IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EGG ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FISH ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MILK ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PEANUT ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SESAME ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SHELLFISH ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOY ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TREE NUT ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY WHEAT ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CLINICS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA FOOD ALLERGY DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA FOOD ALL